Imexon for Relapsed Follicular and Aggressive Lymphomas

NCT01314014 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma
Small Lymphocytic Lymphoma
Marginal Zone Lymphoma
Lymphoplasmacytic Lymphoma
Diffuse Large B Cell Lymphoma
Mantle Cell Lymphoma
Burkitt's Lymphoma

Interventions

DRUG: Imexon

Sponsor

University of Rochester

Collaborators

[object Object]